万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>期刊大全 >>中国国际期刊>>医学综合
您的位置:万维书刊网 >>期刊大全 >>国内SCI期刊>>医药卫生

癌症通讯(英文)(Cancer Communications)(OA学术期刊)(国际刊号) (官网投稿)

简介
《癌症通讯(英文)》(Cancer Communications)(月刊)(前刊名Chinese Journal of Cancer,2018年变更为现刊名),是中山大学肿瘤防治中心主办的肿瘤学专业期刊,主编徐瑞华教授。一直秉承“搭建国际化肿瘤学研究交流平台,促进学科发展”的办刊宗旨,坚持质量第一,社会效益第一的办刊理念,影响力不断扩大:2013-2019连续7年获得“中国最具国际影响力学术期刊”...[显示全部]
本刊为:高质量科技期刊(T1), SCIE(2024版), 目次收录(维普), 知网外文库,外文期刊,
征稿信息

万维提示:

1、该刊只有国际刊号。

2、投稿方式:在线投稿。

3、官网网址:

https://onlinelibrary.wiley.com/journal/25233548

4、投稿系统:https://wiley.atyponrex.com/journal/CAC2

5、主办单位网址:https://www.sysucc.org.cn/

(中山大学肿瘤防治中心)

6、官网邮箱:cancercommun@sysucc.org.cn

7、期刊刊期:月刊,一年出版12期。

8、官方微信公众号:

Cancer CommunicationsCancerCommunications

20241031日星期四

                             

 

《癌症通讯(英文)》(Cancer Communications

期刊简介

 

关于Cancer Communications

Cancer Communications(前刊名Chinese Journal of Cancer2018年变更为现刊名)由中山大学肿瘤防治中心主办,主编徐瑞华教授。该刊202011日起与国际著名三大学术出版社之一Wiley合作出版。

Cancer Communications CC,原刊名Chinese Journal of Cancer)创刊于1982 年,是中山大学肿瘤防治中心主办的肿瘤学专业期刊,主编徐瑞华教授。CC PubmedSCI 收录期刊,2021 年公布的 JCR 影响因子为 10.392

CC 一直秉承搭建国际化肿瘤学研究交流平台,促进学科发展的办刊宗旨,坚持质量第一,社会效益第一的办刊理念,影响力不断扩大:2013-2019连续 7 年获得中国最具国际影响力学术期刊称号。

CC 坚持国际化办刊理念,不断拓展杂志的国际稿源,遴选国际知名学者担任评审专家;作为美中抗癌协会(USCACA)会刊,CC 获得了众多海外资深学者的大力支持;2015年至2019年与 Springer-Nature 旗下的BioMed Central合作出版,2020年开始与Wiley合作出版,开拓了CC 的国际化前进道路。

目前,Cancer Communications 被世界权威生物医学检索系统PubMed/MedlineScopus和国际最大的开放获取期刊目录DOAJ等重要数据库收录;采用国际同行评议、完全开放获取的办刊模式。迄今为止,Cancer Communications 已发表来自88个国家/地区近2106个机构(按照所有作者国家与机构计算)的论文千余篇,被108个国家/地区的研究机构引用,积年累计总被引频次超过23000次;发表的多篇文章被领域内著名期刊Nature, Science,  Cell,  Lancet,  The New England Journal of Medicine, Cancer Cell, Stem Cells, Nature Reviews Cancer, Nature Reviews Neurology, Nature Reviews Urology 等引用。

 

《癌症通讯(英文)》(Cancer Communications)作者指南

【官网信息】

 

Author Guidelines

1. Submission

2. Aims and Scope

3. Manuscript Categories and Requirements

4. Preparing the Submission

5. Editorial Policies and Ethical Considerations

6. Author Licensing

7. Publication Process after Acceptance

8. Post Publication

9. Editorial Office Contact Details

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

New submissions should be made via the Research Exchange submission portal https://wiley.atyponrex.com/journal/CAC2. You may check the status of your submission at any time by logging on to submission.wiley.com and clicking the “My Submissions” button. For technical help with the submission system, please review our FAQs or contact submissionhelp@wiley.com.

Free Format submission

Cancer Communications now offers Free Format submission for a simplified and streamlined submission process.

Before you submit, you will need:

Your manuscript: this should be an editable file including text, figures, and tables, or separate files – whichever you prefer. All required sections should be contained in your manuscript, including abstract, introduction, methods, results, and conclusions. Figures and tables should have legends. Figures should be uploaded in the highest resolution possible. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in separate files. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers, and the editorial office will send it back to you for revision. Your manuscript may also be sent back to you for revision if the quality of English language is poor.

An ORCID ID, freely available at https://orcid.org. (Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.)

The title page of the manuscript, including:

Your co-author details, including affiliation and email address. (Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.)

Statements relating to our ethics and integrity policies, which may include any of the following (Why are these important? We need to uphold rigorous ethical standards for the research we consider for publication):

data availability statement

funding statement

conflict of interest disclosure

ethics approval statement

patient consent statement

permission to reproduce material from other sources

clinical trial registration

Data protection:

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.

更多详情:

https://onlinelibrary.wiley.com/page/journal/25233548/homepage/author-guidelines


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭